Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is soliciting Capricor Therapeutics investors to join an investigation into potential federal securities law violations. The investigation follows an FDA advisory committee vote that found no evidence supporting the effectiveness of deramiocel, triggering a 65% stock price decline.
Key figures
- Stock decline pct
- 65%
- Advisory committee vote for
- 3
- Advisory committee vote against
- 9
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.